Results with the phosphodiesterase 3B gene (PDE3B), the inhibitor of which augments apoptosis of chronic lymphocytic leukemia [14], emphasized the association with CDDP resistance based on canonical pathway analysis, suggesting that the PDE3B gene may hold the key to the molecular mechanisms of resistant human cancer that might be chemotherapeutic molecular markers for choosing the appropriate chemotherapy for this disease. Here, PDE3B is linked to B-cell chronic lymphocytic leukemia.